New directions in cardiac transplantation

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 455-471

  Al Khaldi, Abdulaziz ^a   Robbins, Robert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac allograft vasculopathy; Heart transplant; Immunosuppression; Rejection

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STATINE DERIVATIVE;

ALLOGRAFT; ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; DONOR SELECTION; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT PLANNING; VASCULAR DISEASE;

GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; PATIENT SELECTION; TISSUE AND ORGAN PROCUREMENT;

EID: 32944475448     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.082704.130518     Document Type: Review

References (103)

1. Robbins RC, Barlow CW, Oyer PE, et al. 1999. Thirty years of cardiac transplantation at Stanford University. J. Thorac. Cardiovasc. Surg. 117:939-51
2. Morgan JA, John R, Weinberg AD, et al. 2004. Heart transplantation in diabetic recipients: a decade review of 161 patients at Columbia Presbyterian. J. Thorac. Cardiovasc. Surg. 127:1486-92
3. Lang CC, Beniaminovitz A, Edwards N, et al. 2003. Morbidity and mortality in diabetic patients following cardiac transplantation. J. Heart Lung Transplant. 22:244-49
4. Czerny M, Sahin V, Fasching P, et al. 2002. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia 45:1498-508
5. Nardo B, Beltempo P, Bertelli R, et al. 2004. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant. Proc. 36:645-47
6. Alloni A, Pellegrini C, Ragni T, et al. 2004. Heart transplantation in patients with amyloidosis: single-center experience. Transplant. Proc. 36:643-44
7. Grazi GL, Cescon M, Salvi F, et al. 2003. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl. 9:986-92
8. Bisleri G, Morgan JA, Deng MC, et al. 2003. Should HIV-positive recipients undergo heart transplantation? J. Thorac. Cardiovasc. Surg. 126:1639-40
9. Calabrese LH, Albrecht M, Young J, et al. 2003. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N. Engl. J. Med. 348:2323-28
10. Hosenpud JD, Pamidi SR, Fiol BS, et al. 2000. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J. Heart Lung Transplant. 19:781-85
11. Castella M, Tenderich G, Koerner MM, et al. 2001. Outcome of heart transplantation in patients previously infected with hepatitis C virus. J. Heart Lung Transplant. 20:595-98
12. Lake KD, Smith CI, LaForest SK, et al. 1997. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J. Heart Lung Transplant. 16:917-21
13. Milfred SK, Lake KD, Anderson DJ, et al. 1994. Practices of cardiothoracic transplant centers regarding hepatitis C-seropositive candidates and donors. Transplantation 57:568-72
14. Espinoza C, Manito N, Roca J, et al. 1999. Reversibility of pulmonary hypertension in patients evaluated for orthotopic heart transplantation: importance in the postoperative morbidity and mortality. Transplant. Proc. 31:2503-4
15. Tenderich G, Koerner MM, Stuettgen B, et al. 2000. Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation. J. Cardiovasc. Surg. 41:215-19
16. Vermes E, Kirsch M, Houel R, et al. 2001. Immunologic events and long-term survival after combined heart and kidney transplantation: a 12-year single-center experience. J. Heart Lung Transplant. 20:1084-91
17. Haynes H, Farroni J. 2004. Successful combined heart-liver transplantation in a patient with hemochromatosis. Prog. Transplant. 14:39-40
18. Morgan JA, John R, Weinberg AD, et al. 2003. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann. Thorac. Surg. 76:1982-87
19. Blanche C, Blanche DA, Kearney B, et al. 2001. Heart transplantation in patients seventy years of age and older: a comparative analysis of outcome. J. Thorac. Cardiovasc. Surg. 121:532-41
20. Taylor DO, Edwards LB, Boucek MM, et al. 2004. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J. Heart Lung Transplant. 23(7):796-803
21. Gammie JS, Edwards LB, Griffith BP, et al. 2004. Optimal timing of cardiac transplantation after ventricular assist device implantation. J. Thorac. Cardiovasc. Surg. 127:1789-99
22. West LJ, Pollock-Barziv SM, Dipchand AI, et al. 2001. ABO-incompatible heart transplantation in infants. N. Engl. J. Med. 344:793-800
23. Zaroff JG, Rosengard BR, Armstrong WF, et al. 2002. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 106:836-41
24. Lietz K, John R, Mancini DM, et al. 2004. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; implications for donor selection criteria. J. Am. Coll. Cardiol. 43:1553-61
25. Razzouk AJ, Chinnock RE, Gundry SR, et al. 1996. Transplantation as a primary treatment for hypoplastic left heart syndrome: intermediate-term results. Ann. Thorac. Surg. 62:1-7
26. Bailey LL, Gundry SR, Razzouk AJ, et al. 1993. Bless the babies: one hundred fifteen late survivors of heart transplantation during the first year of life. J. Thorac. Cardiovasc. Surg. 105:805-14
27. Kawauchi M, Gundry SR, de Begona JA, et al. 1993. Prolonged preservation of human pediatric hearts for transplantation: correlation of ischemic time and subsequent function. J. Heart Lung Transplant. 12:55-58
28. Mitchell MB, Campbell DN, Clarke DR, et al. 1998. Infant heart transplantation: improved intermediate results. J. Thorac. Cardiovasc. Surg. 116:242-52
29. Canter C, Naftel D, Caldwell R, et al. 1997. Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. The Pediatric Heart Transplant Study. Circulation 96:227-31
30. Fernandez J, Aranda J, Mabbot S, et al. 2001. Overseas procurement of donor hearts: ischemic time effect on postoperative outcomes. Transplant. Proc. 33:3803-4
31. Ibrahim M, Masters RG, Hendry PJ, et al. 1995. Determinants of hospital survival after cardiac transplantation. Ann. Thorac. Surg. 59:604-8
32. Briganti EM, Bergin PJ, Rosenfeldt FL, et al. 1995. Successful long-term outcome with prolonged ischemic time cardiac allografts. J. Heart Lung Transplant. 14:840-45
33. Del Rizzo DF, Menkis AH, Pflugfelder PW, et al. 1999. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J. Heart Lung Transplant. 18:310-19
34. Mullen JC, Bentley MJ, Modry DL, et al. 2001. Extended donor ischemic times and recipient outcome after orthotopic cardiac transplantation. Can. J. Cardiol. 17:421-26
35. Morgan JA, John R, Weinberg AD, et al. 2003. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation. J. Thorac. Cardiovasc. Surg. 126:1624-33
36. Shumway NE, Lower RR, Stofer RC. 1966. Transplantation of the heart. Adv. Surg. 2:265-84
37. Sievers HH, Weyand M, Kraatz EG, et al. 1991. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. Thorac. Cardiovasc. Surg. 39:70-72
38. Sarsam MA, Campbell CS, Yonan NA, et al. 1993. An alternative surgical technique in orthotopic cardiac transplantation. J. Card. Surg. 8:344-49
39. El Gamel A, Deiraniya AK, Rahman AN, et al. 1996. Orthotopic heart transplantation hemodynamics: Does atrial preservation improve cardiac output after transplantation? J. Heart Lung Transplant. 15:564-71
40. El Gamel A, Yonan NA, Grant S, et al. 1995. Orthotopic cardiac transplantation: a comparison of standard and bicaval Wythenshawe techniques. J. Thorac. Cardiovasc. Surg. 109:721-29
41. Sievers HH, Leyh R, Jahnke A, et al. 1994. Bicaval versus atrial anastomoses in cardiac transplantation. Right atrial dimension and tricuspid valve function at rest and during exercise up to thirty-six months after transplantation. J. Thorac. Cardiovasc. Surg. 108:780-84
42. Rothman SA, Jeevanandam V, Combs WG, et al. 1996. Eliminating bradyarrhythmias after orthotopic heart transplantation. Circulation 94:II278-II282
43. Aziz TM, Burgess MI, El Gamel A, et al. 1999. Orthotopic cardiac transplantation technique: a survey of current practice. Ann. Thorac. Surg. 68:1242-46
44. Jeevanandam V, Russell H, Mather P, et al. 2004. A one-year comparison of prophylactic donor tricuspid annuloplasty in heart transplantation. Ann. Thorac. Surg. 78(3):759-66
45. Dreyfus G, Jebara V, Mihaileanu S, et al. 1991. Total orthotopic heart transplantation: an alternative to the standard technique. Ann. Thorac. Surg. 52:1181-84
46. Barnard CN, Losman JG. 1975. Left ventricular bypass. S. Afr. Med. J. 49:303-12
47. Bleasdale RA, Banner NR, Anyanwu AC, et al. Determinants of outcome after heterotopic heart transplantation. J. Heart Lung Transplant. 21:867-73
48. Ridley PD, Khaghani A, Musumeci F, et al. 1992. Heterotopic heart transplantation and recipient heart operation in ischemic heart disease. Ann. Thorac. Surg. 54:333-37
49. Desruennes M, Muneretto C, Gandjbakhch I, et al. 1989. Heterotopic heart transplantation: current status in 1988. J. Heart Transplant. 8:479-85
50. Kawaguchi A, Gandjbakhch I, Pavie A, et al. 1989. Factors affecting survival after heterotopic heart transplantation. J. Thorac. Cardiovasc. Surg. 98:928-34
51. Nakatani T, Frazier OH, Lammermeier DE, et al. 1989. Heterotopic heart transplantation: a reliable option for a select group of high-risk patients. J. Heart Transplant. 8:40-47
52. Beniaminovitz A, Itescu S, Lietz K, et al. 2000. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with monoclonal antibody. N. Engl. J. Med. 342:613-19
53. Queen C, Schneider WP, Selick HE, et al. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86:10029-33
54. Vincenti F, Nashan B, Light S. 1998. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant. Proc. 30:2155-58
55. Cantarovich M, Metrakos P, Giannetti N, et al. 2002. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 73:1169-72
56. Abraham RT. 1998. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol. 10:330-36
57. Ankersmit HJ, Roth G, Zuckermann A, et al. 2003. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. Am. J. Transplant. 3:231-34
58. Straatman LP, Coles JG. 2000. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 70:541-43
59. Haddad H, MacNeil DM, Howlett J, et al. 2000. Sirolimus, a new potent immunosuppressant agent for refractory cardiac transplantation rejection: two case reports. Can. J. Cardiol. 16:221-24
60. Snell GI, Levvey BJ, Chin W, et al. 2002. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J. Heart Lung Transplant. 21:540-46
61. Russ GR, Campbell S, Chadban S, et al. 2003. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant. Proc. 35:115S-7S
62. Groetzner J, Meiser B, Landwehr P, et al. 2004. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77:568-74
63. Groetzner J, Kaczmarek I, Landwehr P, et al. 2004. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur. J. Cardiothorac. Surg. 25:333-41
64. Meiser BM, Billingham ME, Morris RE. 1991. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 338:1297-98
65. Eisen HJ, Tuzcu EM, Dorent R, et al. 2003. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349:847-58
66. Mancini D, Pinney S, Burkhoff D, et al. 2003. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108:48-53
67. Ruygrok PN, Webber B, Faddy S, et al. 2003. Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. J. Heart Lung Transplant. 22:1276-79
68. Dean PG, Lund WJ, Larson TS, et al. 2004. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77:1555-61
69. Groetzner J, Kur F, Spelsberg F, et al. 2004. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant. 23:632-38
70. Kahan BD, Dunn J, Fitts C, et al. 1994. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant. Proc. 26:2940-43
71. Levy G, Burra P, Cavallari A, et al. 2002. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 73:953-59
72. Cantarovich M, Elstein E, de Varennes B, et al. 1999. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 68:1839-42
73. Cantarovich M, Quantz M, Elstein E, et al. 2000. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction. Transplant. Proc. 32:446-48
74. Morton JM, Aboyoun CL, Malouf MA, et al. 2004. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J. Heart Lung Transplant. 23:1035-39
75. Caves PK, Stinson EB, Billingham ME, et al. 1973. Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J. Thorac. Cardiovasc. Surg. 66:461-66
76. Caves PK, Stinson EB, Billingham ME, et al. 1974. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet 1:821-26
77. Billingham ME. 1979. Some recent advances in cardiac pathology. Hum. Pathol. 10:367-86
78. Mehra MR, Kobashigawa JA. 2004. Advances in heart and lung transplantation 2004: report from the 24th International Society for Heart and Lung Transplantation Annual Meeting, San Francisco, April 21-24, 2004. J. Heart Lung Transplant. 23:925-30
79. Deng MC, Mehra MR, Eisen HJ. 2003. Cardiac allograft monitoring using a novel clinical algorithm based on peripheral leukocyte gene expression profiling. Circulation 108:1801
80. Mehra MR, Kobashigawa J, Hunt S, et al. 2004. Molecular testing and prediction of clinical outcome in heart transplantation: a prospective multicenter trial. J. Heart Lung Transplant. 23:S106
81. Costanzo MR, Naftel DC, Pritzker MR, et al. 1998. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J. Heart Lung Transplant. 17:744-53
82. Valantine H, Rickenbacker P, Kemna M, et al. 2001. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 103:2144-52
83. Costanzo-Nordin MR. 1992. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J. Heart Lung Transplant. 11:S90-103
84. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561-66
85. Kobashigawa JA, Miller L, Yeung A, et al. 1995. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. J. Heart Lung Transplant. 14:S221-S226
86. Valantine H. 2004. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. 23:S187-S193
87. Olivari MT, Kubo SH, Braunlin EA, et al. 1990. Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation. Circulation 82:IV276-IV280
88. Taylor DO, Ensley RD, Olsen SL, et al. 1994. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J. Heart Lung Transplant. 13:571-82
89. Kobashigawa J, Miller L, Renlund D, et al. 1998. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66:507-15
90. Radovancevic B, McGiffin DC, Kobashigawa JA, et al. 2003. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J. Heart Lung Transplant. 22:862-68
91. Esmore DS, Spratt PM, Keogh AM, et al. 1989. Cyclosporine and azathioprine immunosuppression without maintenance steroids: a prospective randomized trial. J. Heart Transplant. 8:194-99
92. Lee KF, Pierce JD, Hess ML, et al. 1991. Cardiac transplantation with corticosteroid-free immunosuppression: long-term results. Ann. Thorac. Surg. 52:211-17
93. Renlund DG, O'Connell JB, Gilbert EM, et al. 1987. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J. Heart Transplant. 6:71-78
94. Kobashigawa JA, Stevenson LW, Brownfield ED, et al. 1992. Initial success of steroid weaning late after heart transplantation. J. Heart Lung Transplant. 11:428-30
95. Miller LW, Wolford T, McBride LR, et al. 1992. Successful withdrawal of corticosteroids in heart transplantation. J. Heart Lung Transplant. 11:431-34
96. Oaks TE, Wannenberg T, Close SA, et al. 2001. Steroid-free maintenance immunosuppression after heart transplantation. Ann. Thorac. Surg. 72:102-6
97. Felkel TO, Smith AL, Reichenspurner HC, et al. 2002. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J. Heart Lung Transplant. 21:530-39
98. Schroeder JS, Gao SZ, Alderman EL, et al. 1993. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N. Engl. J. Med. 328:164-70
99. Kobashigawa JA, Katznelson S, Laks H, et al. 1995. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:621-27
100. Mehra MR, Ventura HO, Smart FW, et al. 1995. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am. J. Cardiol. 75:853-54
101. Redonnet M, Tron C, Koning R, et al. 2000. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant. Proc. 32:463-65
102. Halle AA III, Wilson RF, Massin EK, et al. 1992. Coronary angioplasty in cardiac transplant patients. Results of a multicenter study. Circulation 86:458-62
103. Halle AA III, DiSciascio G, Massin EK, et al. 1995. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J. Am. Coll. Cardiol. 26:120-28